Inclusion Criteria:

- ECOG performance status score 0-1.

- Chemo-naïve patients.

- Histologically/cytologically confirmed diagnosis of rectal adenocarcinoma (clinically
stage mT3 or mT4), either considered (1)inoperable, or (2)locally advanced, where
histologically confirmed curative resection is considered unlikely.

- Evaluable measurable disease on imaging with MRI/CT to allow for response assessment.

- Adequate haematological, renal and liver functions as follows:

- ANC > 3000ml

- Platelet count > 100,000 ml

- Urea & Serum Creatinine < 1.5 X upper limit of normal value

- Total serum bilirubin < 1.5 X upper limit of normal value

- ALT & AST < 3 X upper limit of normal value

Exclusion Criteria:

- Prior chemotherapy.

- Documented allergy to oxaliplatin or capecitabine.

- Prior radiotherapy to pelvis.

- Previous or concurrent malignancies at other sites with the exception of basal or
squamous cell carcinoma of the skin.

- Pregnant or lactating females (with negative pregnancy test documentation in
pre-menopausal female patients).

- Currently participating into another clinical trial with any investigational drug in
the previous 30 days.

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.